Literature DB >> 18383153

Multiple intracranial tumors in Philadelphia chromosome positive acute lymphoblastic leukemia: successful treatment following aggressive supportive care, early cranial radiation, high dose chemotherapy and imatinib.

Geoff D E Cuvelier1, Aleksander M Vitali, Jason C Ford, David B Dix.   

Abstract

We report the first case of multiple intracranial tumors ("chloromas") at diagnosis of Philadelphia chromosome positive acute lymphoblastic leukemia. The patient presented comatose with signs of cerebral herniation. Initial management of raised intracranial pressure and hyperleukocytosis followed by emergent whole brain radiation therapy reversed the life-threatening neurological signs. High-dose chemotherapy combined with daily imatinib mesylate induced a rapid and sustained bone marrow remission. Ongoing rehabilitation resulted in a near complete neurological recovery within 6 months of diagnosis. This outcome justifies aggressive early management of increased intracranial pressure and hyperleukocytosis in future similar presentations. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18383153     DOI: 10.1002/pbc.21562

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  3 in total

1.  Multiple intracranial tumors in Philadelphia chromosome-positive acute lymphoblastic leukemia.

Authors:  Naoki Hatakeyama; Tsukasa Hori; Masaki Yamamoto; Natsuko Inazawa; Keita Igarashi; Hiroyuki Tsutsumi; Nobuhiro Suzuki
Journal:  Int J Hematol       Date:  2013-03-24       Impact factor: 2.490

2.  Tumefactive intracranial presentation of precursor B-cell acute lymphoblastic leukemia.

Authors:  Craig M Forester; Chi L Braunreiter; Hasan Yaish; Gary L Hedlund; Zeinab Afify
Journal:  Pediatr Radiol       Date:  2009-09-10

Review 3.  Management of Hyperleukocytosis.

Authors:  Antonio Ruggiero; Daniela Rizzo; Maria Amato; Riccardo Riccardi
Journal:  Curr Treat Options Oncol       Date:  2016-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.